Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  HIV Infection

  Free Subscription


24.09.2018

14 AIDS
7 AIDS Res Hum Retroviruses
1 Antimicrob Agents Chemother
1 Antivir Ther
6 Clin Infect Dis
13 J Acquir Immune Defic Syndr
2 J Am Acad Dermatol
1 J Clin Invest
2 J Infect Dis
1 J Virol
1 Lancet Glob Health
2 Lancet HIV
1 MMWR Morb Mortal Wkly Rep
1 N Engl J Med
3 Nature
3 Pediatr Infect Dis J
1 PLoS Comput Biol
1 PLoS Med
13 PLoS One
1 PLoS Pathog
1 Proc Natl Acad Sci U S A
2 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AIDS

  1. ROHNER E
    Non-Hodgkin lymphoma risk in adults living with HIV across five continents: a multicohort study.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002003.
    PubMed     Text format     Abstract available

  2. HARTER ZJ, Agarwal S, Dalvi P, Voelkel NF, et al
    Drug abuse and HIV related pulmonary hypertension: double hit injury.
    AIDS. 2018 Sep 18. doi: 10.1097/QAD.0000000000002030.
    PubMed     Text format     Abstract available

  3. LUO Z, Ogunrinde E, Li M, Zhang L, et al
    Increased influenza-specific antibody avidity in HIV-infected females compared to HIV-infected males on antiretroviral therapy.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002022.
    PubMed     Text format     Abstract available

  4. BANDERA A, Colella E, Clerici M, Rizzardini G, et al
    The contribution of immune activation and accelerated aging in multiple myeloma occurring in HIV-infected population.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002015.
    PubMed     Text format     Abstract available

  5. HOARE J, Fouche JP, Phillips N, Joska JA, et al
    Structural brain changes in perinatally HIV infected young adolescents in South Africa.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002024.
    PubMed     Text format     Abstract available

  6. LEECH AA, Burgess JF Jr, Sullivan M, Kuohung W, et al
    Cost-effectiveness of pre-exposure prophylaxis for HIV prevention for conception in the United States.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002014.
    PubMed     Text format     Abstract available

  7. HARRINGTON BJ, Pence BW, Maliwichi M, Jumbe AN, et al
    Probable antenatal depression at antiretroviral initiation and postpartum viral suppression and engagement in Option B.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002025.
    PubMed     Text format     Abstract available

  8. MZEMBE T, Mclean E, Khan PY, Koole O, et al
    Risk of Mycobacterium tuberculosis transmission in an antiretroviral therapy clinic.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002006.
    PubMed     Text format     Abstract available

  9. SHAIYKOVA A, Pasquet A, Goujard C, Lion G, et al
    Reduced bone mineral density among HIV-infected, virologically controlled young men: Prevalence and associated factors.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002001.
    PubMed     Text format     Abstract available

  10. FORTHAL DN, Finzi A
    Antibody-Dependent Cellular Cytotoxicity (ADCC) in HIV Infection.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002011.
    PubMed     Text format    

  11. BIBERT S, Wojtowicz A, Taffe P, Tarr PE, et al
    IFNL3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002004.
    PubMed     Text format     Abstract available

  12. KELLER MJ, Burk RD, Massad LS, Eltoum IE, et al
    Racial differences in HPV types amongst US women with HIV and cervical precancer.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002005.
    PubMed     Text format     Abstract available

  13. KENYON C
    We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in PrEP cohorts.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002020.
    PubMed     Text format     Abstract available

  14. TAYLOR HE, Calantone NA, D'Aquila RT
    mTOR signaling mediates effects of common gamma-chain cytokines on T cell proliferation and exhaustion: implications for HIV-1 persistence and cure research.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000001997.
    PubMed     Text format     Abstract available


    AIDS Res Hum Retroviruses

  15. MA P, Ge Z, Feng Y, Ou W, et al
    Near full-length genome sequence of a novel HIV-1 second-generation recombinant form (CRF01_AE/CRF07_BC) detected among men who have sex with men in Tianjin, China.
    AIDS Res Hum Retroviruses. 2018 Sep 19. doi: 10.1089/AID.2018.0177.
    PubMed     Text format     Abstract available

  16. SCHWEITZER F, Tarantelli R, Rayens E, Kling H, et al
    Monocyte and alveolar macrophage skewing is associated with the development of pulmonary arterial hypertension (PAH) in a primate model of HIV-infection.
    AIDS Res Hum Retroviruses. 2018 Sep 19. doi: 10.1089/AID.2018.0132.
    PubMed     Text format     Abstract available

  17. OU W, Li K, Feng Y, Huang Q, et al
    Characterization of a New HIV-1 CRF01_AE/B Recombinant Virus Form Among Men Who Have Sex with Men in Shanghai, China.
    AIDS Res Hum Retroviruses. 2018 Sep 19. doi: 10.1089/AID.2018.0197.
    PubMed     Text format     Abstract available

  18. JEONG W, Jung IY, Choi H, Kim JH, et al
    Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea.
    AIDS Res Hum Retroviruses. 2018 Sep 19. doi: 10.1089/AID.2018.0213.
    PubMed     Text format     Abstract available

  19. CALDER BJ, Schieffer RJ, Bryndza Tfaily E, D'Aquila RT, et al
    Qualitative Consumer Research on Acceptance of Long-acting PrEP Products among MSM and Medical Practitioners in the United States.
    AIDS Res Hum Retroviruses. 2018 Sep 19. doi: 10.1089/AID.2018.0214.
    PubMed     Text format     Abstract available

  20. UEDA S, Witaningrum AM, Khairunisa SQ, Kotaki T, et al
    Genetic Diversity and Drug Resistance of HIV-1 Circulating in North Sulawesi, Indonesia.
    AIDS Res Hum Retroviruses. 2018 Sep 19. doi: 10.1089/AID.2018.0221.
    PubMed     Text format     Abstract available

  21. DUFRASNE FE, Lucchetti M, Dessilly G, Ruelle JP, et al
    An insertion of seven amino acids in the envelope cytoplasmic tail of HIV-2 selected during disease progression enhances viral replication.
    AIDS Res Hum Retroviruses. 2018 Sep 19. doi: 10.1089/AID.2018.0129.
    PubMed     Text format     Abstract available


    Antimicrob Agents Chemother

  22. DIAN S, Yunivita V, Ganiem AR, Pramaesya T, et al
    A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study.
    Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01014.
    PubMed     Text format     Abstract available


    Antivir Ther

  23. LADAK F, Socias E, Nolan S, Dong H, et al
    Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Antivir Ther. 2018 Sep 19. doi: 10.3851/IMP3265.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  24. ROBERTSON KR, Jiang H, Kumwenda J, Supparatpinyo K, et al
    HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings.
    Clin Infect Dis. 2018 Sep 13. pii: 5096722. doi: 10.1093.
    PubMed     Text format     Abstract available

  25. HADDAD E, Chabane K, Jaureguiberry S, Monsel G, et al
    Holistic approach in patients with presumed Lyme borreliosis leads to less than 10% of confirmation and more than 80% of antibiotics failure.
    Clin Infect Dis. 2018 Sep 18. pii: 5099448. doi: 10.1093.
    PubMed     Text format     Abstract available

  26. LIU AY, Vittinghoff E, von Felten P, Amico KR, et al
    Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Pre-exposure Prophylaxis among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study.
    Clin Infect Dis. 2018 Sep 15. pii: 5098440. doi: 10.1093.
    PubMed     Text format     Abstract available

  27. WIJNEN BFM, Oberje EJM, Evers SMAA, Prins JM, et al
    Cost-effectiveness and Cost-utility of the Adherence Improving Self-management Strategy in Human Immunodeficiency Virus Care: A Trial-based Economic Evaluation.
    Clin Infect Dis. 2018 Sep 14. pii: 5098230. doi: 10.1093.
    PubMed     Text format     Abstract available

  28. SHERMAN KE, Abdel-Hameed E, Rouster SD, Shata MTM, et al
    Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation through Mutation or Therapeutic Blockade.
    Clin Infect Dis. 2018 Sep 20. pii: 5104288. doi: 10.1093.
    PubMed     Text format     Abstract available

  29. HSUE PY, Ribaudo HJ, Deeks SG, Bell T, et al
    Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.
    Clin Infect Dis. 2018 Sep 14. pii: 5096825. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Acquir Immune Defic Syndr

  30. COTTINGHAM MD, Kalbaugh JM, Swezey T, Fisher JA, et al
    Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.
    J Acquir Immune Defic Syndr. 2018;79 Suppl 1:S30-S36.
    PubMed     Text format     Abstract available

  31. DURIER C, Desaint C, Launay O
    Social and Behavioral Consequences of Participation in HIV Preventive Vaccine Trials in the ANRS COHVAC Cohort.
    J Acquir Immune Defic Syndr. 2018;79 Suppl 1:S37-S50.
    PubMed     Text format     Abstract available

  32. COUDERC M
    Being "False Positive": An "Inconvenience"? Debates and Questions Regarding the Notion of Vaccine-Induced Seropositivity (VISP) in the Recruitment of Healthy Volunteers for a Preventive Anti-HIV Vaccine Trial.
    J Acquir Immune Defic Syndr. 2018;79 Suppl 1:S20-S29.
    PubMed     Text format     Abstract available

  33. OLLIVIER-YANIV C
    Recruitment and Engagement in Preventive Clinical Trials: Interdependencies and Mediation.
    J Acquir Immune Defic Syndr. 2018;79 Suppl 1:S3-S7.
    PubMed     Text format     Abstract available

  34. RAFFUL C, Jain S, Sun X, Strathdee SA, et al
    Identification of a Syndemic of Blood-Borne Disease Transmission and Injection drug Use Initiation at the US-Mexico Border.
    J Acquir Immune Defic Syndr. 2018 Sep 14. doi: 10.1097/QAI.0000000000001858.
    PubMed     Text format     Abstract available

  35. WORODRIA W, Emily C, Andama A, Sanyu I, et al
    Predictors of Mortality among Hospitalized Patients with Lower Respiratory Tract Infections in a High HIV Burden Setting.
    J Acquir Immune Defic Syndr. 2018 Sep 14. doi: 10.1097/QAI.0000000000001855.
    PubMed     Text format     Abstract available

  36. OSTER AM, France AM, Panneer N, Banez Ocfemia MC, et al
    Identifying Clusters of Recent and Rapid HIV Transmission Through Analysis of Molecular Surveillance Data.
    J Acquir Immune Defic Syndr. 2018 Sep 7. doi: 10.1097/QAI.0000000000001856.
    PubMed     Text format     Abstract available

  37. GIAMI A, Linard F
    HIV Vaccine Trials: Ethical, Psychological, and Psychological-Social Aspects (1991-1996).
    J Acquir Immune Defic Syndr. 2018;79 Suppl 1:S51-S58.
    PubMed     Text format     Abstract available

  38. FILLIEULE O
    Logics of Commitment in Vaccine Trials of the ANRS Cohorts 1992-2001.
    J Acquir Immune Defic Syndr. 2018;79 Suppl 1:S59-S68.
    PubMed     Text format     Abstract available

  39. LE MARCIS F
    Postface: Meaning of the Experiment and Implications of the Experience.
    J Acquir Immune Defic Syndr. 2018;79 Suppl 1:S69-S73.
    PubMed     Text format     Abstract available

  40. GEORGE EC, Bucciardini R, Richert L, Dedes N, et al
    Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results from NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination with Tenofovir/Emtricitabine or Raltegravir.
    J Acquir Immune Defic Syndr. 2018 Sep 3. doi: 10.1097/QAI.0000000000001844.
    PubMed     Text format     Abstract available

  41. SINGH RP, Shaik JSB, Skoura N, Joshi S, et al
    Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
    J Acquir Immune Defic Syndr. 2018 Sep 14. doi: 10.1097/QAI.0000000000001859.
    PubMed     Text format     Abstract available

  42. PALANEE-PHILLIPS T, Roberts ST, Reddy K, Vaneshree Govender, et al
    Impact of partner-related social harms on women's adherence to the dapivirine vaginal ring during a phase III trial.
    J Acquir Immune Defic Syndr. 2018 Sep 18. doi: 10.1097/QAI.0000000000001866.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  43. OMLAND SH, Omland LH
    Answer to the comment concerning our article "Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study".
    J Am Acad Dermatol. 2018 Sep 14. pii: S0190-9622(18)32502.
    PubMed     Text format    

  44. MANSH MD, Marks DH
    Reply to: "Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study".
    J Am Acad Dermatol. 2018 Sep 14. pii: S0190-9622(18)32503.
    PubMed     Text format    


    J Clin Invest

  45. ZALENSKAYA IA, Chandra N, Yousefieh N, Fang X, et al
    Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.
    J Clin Invest. 2018 Sep 17. pii: 120583. doi: 10.1172/JCI120583.
    PubMed     Text format     Abstract available


    J Infect Dis

  46. MARRA E, Lin C, Clifford GM
    Type-specific anal human papillomavirus prevalence among men, according to sexual preference and HIV status: a systematic literature review and meta-analysis.
    J Infect Dis. 2018 Sep 20. pii: 5103515. doi: 10.1093.
    PubMed     Text format     Abstract available

  47. GUPTA SK, Liu Z, Sims EC, Repass MJ, et al
    Endothelial Colony Forming Cell Function Is Reduced in HIV.
    J Infect Dis. 2018 Sep 18. pii: 5099934. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Virol

  48. DOMINGUEZ-MOLINA B, Machmach K, Perales C, Tarancon-Diez L, et al
    Toll Like Receptor-7 and -9 agonists improve Hepatitis C Virus replication and infectivity inhibition by plasmacytoid dendritic cells.
    J Virol. 2018 Sep 19. pii: JVI.01219-18. doi: 10.1128/JVI.01219.
    PubMed     Text format     Abstract available


    Lancet Glob Health

  49. SHETE PB, Reid M, Goosby E
    Message to world leaders: we cannot end tuberculosis without addressing the social and economic burden of the disease.
    Lancet Glob Health. 2018 Sep 14. pii: S2214-109X(18)30378.
    PubMed     Text format    


    Lancet HIV

  50. GONSALVES GS, Crawford FW
    Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-15: a modelling study.
    Lancet HIV. 2018 Sep 13. pii: S2352-3018(18)30176.
    PubMed     Text format     Abstract available

  51. BEYRER C
    No more Scott Counties.
    Lancet HIV. 2018 Sep 13. pii: S2352-3018(18)30212.
    PubMed     Text format    


    MMWR Morb Mortal Wkly Rep

  52. MITSCH A, Singh S, Li J, Balaji A, et al
    Age-Associated Trends in Diagnosis and Prevalence of Infection with HIV Among Men Who Have Sex with Men - United States, 2008-2016.
    MMWR Morb Mortal Wkly Rep. 2018;67:1025-1031.
    PubMed     Text format     Abstract available


    N Engl J Med

  53. GOLDSTEIN RH, Streed CG Jr, Cahill SR
    Being PrEPared - Preexposure Prophylaxis and HIV Disparities.
    N Engl J Med. 2018 Sep 19. doi: 10.1056/NEJMp1804306.
    PubMed     Text format    


    Nature

  54. BERTAGNOLLI LN, White JA, Simonetti FR, Beg SA, et al
    The role of CD32 during HIV-1 infection.
    Nature. 2018;561:E17-E19.
    PubMed     Text format    

  55. OSUNA CE, Lim SY, Kublin JL, Apps R, et al
    Evidence that CD32a does not mark the HIV-1 latent reservoir.
    Nature. 2018;561:E20-E28.
    PubMed     Text format    

  56. PEREZ L, Anderson J, Chipman J, Thorkelson A, et al
    Conflicting evidence for HIV enrichment in CD32(+) CD4 T cells.
    Nature. 2018;561:E9-E16.
    PubMed     Text format    


    Pediatr Infect Dis J

  57. GAFAR F, Arifin H, Jurnalis YD, Yani FF, et al
    Antituberculosis Drug-Induced Liver Injury in Children: Incidence and Risk Factors During the Two-Month Intensive Phase of Therapy.
    Pediatr Infect Dis J. 2018 Sep 18. doi: 10.1097/INF.0000000000002192.
    PubMed     Text format     Abstract available

  58. LE ROUX SM, Donald KA, Kroon M, Phillips TK, et al
    HIV Viremia During Pregnancy and Neurodevelopment of HIV-Exposed Uninfected Children in the Context of Universal Antiretroviral Therapy and Breastfeeding: A Prospective Study.
    Pediatr Infect Dis J. 2018 Sep 18. doi: 10.1097/INF.0000000000002193.
    PubMed     Text format     Abstract available

  59. CHATPORNVORARUX S, Maleesatharn A, Rungmaitree S, Wittawatmongkol O, et al
    Delayed Seroreversion in HIV-Exposed Uninfected Infants.
    Pediatr Infect Dis J. 2018 Sep 19. doi: 10.1097/INF.0000000000002196.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  60. NA H, Song G
    All-atom normal mode dynamics of HIV-1 capsid.
    PLoS Comput Biol. 2018;14:e1006456.
    PubMed     Text format     Abstract available


    PLoS Med

  61. GELDSETZER P, Francis JM, Sando D, Asmus G, et al
    Community delivery of antiretroviral drugs: A non-inferiority cluster-randomized pragmatic trial in Dar es Salaam, Tanzania.
    PLoS Med. 2018;15:e1002659.
    PubMed     Text format     Abstract available


    PLoS One

  62. HABIYAMBERE V, Dongmo Nguimfack B, Vojnov L, Ford N, et al
    Forecasting the global demand for HIV monitoring and diagnostic tests: A 2016-2021 analysis.
    PLoS One. 2018;13:e0201341.
    PubMed     Text format     Abstract available

  63. DAS S, Opoku J, Allston A, Kharfen M, et al
    Detecting spatial clusters of HIV and hepatitis coinfections.
    PLoS One. 2018;13:e0203674.
    PubMed     Text format     Abstract available

  64. STEVENS ER, Li L, Nucifora KA, Zhou Q, et al
    Cost-effectiveness of a combination strategy to enhance the HIV care continuum in Swaziland: Link4Health.
    PLoS One. 2018;13:e0204245.
    PubMed     Text format     Abstract available

  65. DOSHI RH, Sande E, Ogwal M, Kiyingi H, et al
    Progress toward UNAIDS 90-90-90 targets: A respondent-driven survey among female sex workers in Kampala, Uganda.
    PLoS One. 2018;13:e0201352.
    PubMed     Text format     Abstract available


  66. Correction: Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India.
    PLoS One. 2018;13:e0204476.
    PubMed     Text format     Abstract available

  67. MUSYOKI H, Bhattacharjee P, Blanchard AK, Kioko J, et al
    Changes in HIV prevention programme outcomes among key populations in Kenya: Data from periodic surveys.
    PLoS One. 2018;13:e0203784.
    PubMed     Text format     Abstract available

  68. NGOM NF, Faye MA, Ndiaye K, Thiam A, et al
    ART initiation in an outpatient treatment center in Dakar, Senegal: A retrospective cohort analysis (1998-2015).
    PLoS One. 2018;13:e0202984.
    PubMed     Text format     Abstract available

  69. KATISI M, Daniel M
    Exploring the roots of antagony in the safe male circumcision partnership in Botswana.
    PLoS One. 2018;13:e0200803.
    PubMed     Text format     Abstract available

  70. ELIZAGA ML, Li SS, Kochar NK, Wilson GJ, et al
    Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
    PLoS One. 2018;13:e0202753.
    PubMed     Text format     Abstract available

  71. AMANKWAA I, Boateng D, Quansah DY, Akuoko CP, et al
    Effectiveness of short message services and voice call interventions for antiretroviral therapy adherence and other outcomes: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0204091.
    PubMed     Text format     Abstract available

  72. ALLAVENA C, Hanf M, Rey D, Duvivier C, et al
    Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.
    PLoS One. 2018;13:e0203895.
    PubMed     Text format     Abstract available

  73. GRIMALDI M, Stillitano I, Amodio G, Santoro A, et al
    Structural basis of antiviral activity of peptides from MPER of FIV gp36.
    PLoS One. 2018;13:e0204042.
    PubMed     Text format     Abstract available

  74. GUTIERREZ-VALENCIA A, Garcia C, Viciana P, Milanes-Guisado Y, et al
    No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
    PLoS One. 2018;13:e0203452.
    PubMed     Text format     Abstract available


    PLoS Pathog

  75. AHMED A, Adiga V, Nayak S, Uday Kumar JAJ, et al
    Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis.
    PLoS Pathog. 2018;14:e1007289.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  76. MATTEI S, Tan A, Glass B, Muller B, et al
    High-resolution structures of HIV-1 Gag cleavage mutants determine structural switch for virus maturation.
    Proc Natl Acad Sci U S A. 2018 Sep 14. pii: 1811237115.
    PubMed     Text format     Abstract available


    Vaccine

  77. DENDLE C, Stuart RL, Mulley WR, Holdsworth SR, et al
    Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence.
    Vaccine. 2018 Sep 11. pii: S0264-410X(18)31209.
    PubMed     Text format     Abstract available

  78. PURWAR M, Pokorski JK, Singh P, Bhattacharyya S, et al
    Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles.
    Vaccine. 2018 Sep 14. pii: S0264-410X(18)31001.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: